Wells Fargo & Company started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) in a research report issued on Monday, Marketbeat Ratings reports. The brokerage set an "overweight" rating and a $28.00 price target on the stock. Wells Fargo & Company's target price would indicate a potential upside of 16.57% from the stock's current price.
Several other equities analysts also recently weighed in on KMTS. Piper Sandler started coverage on shares of Kestra Medical Technologies in a report on Monday. They set an "overweight" rating and a $27.00 price target on the stock. Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a research note on Monday. They set a "buy" rating and a $28.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on Kestra Medical Technologies in a research note on Monday. They issued a "neutral" rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $27.67.
Get Our Latest Report on KMTS
Kestra Medical Technologies Stock Down 6.5 %
Kestra Medical Technologies stock traded down $1.68 during trading on Monday, reaching $24.02. The company had a trading volume of 217,488 shares, compared to its average volume of 285,081. Kestra Medical Technologies has a 52 week low of $20.00 and a 52 week high of $26.06.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Further Reading
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
